These observations, along with recognition of improved survival following PD-1 blockade with pembrolizumab among patients with non-small cell lung cancer who had received prior radiation,137 has motivated significant interest in combining radiation with immunotherapy strategies. Here, PDCD1 is linked to non-small cell lung carcinoma.